Description
Calvenza™ EIV/EHV is Equine Rhinopneumonitis-Influenza Killed Virus Vaccine. EIV/EHV is Equine Rhinopneumonitis-Influenza Killed Virus Vaccine.

Features
•Unique EHV-1 equine respiratory origin isolate.
•Stimulates antibody to EHV-1 & EVH-4.
•Proven efficacious against EHV-1 & EHV-4 in challenge studies.
•Incorporates North American (Kentucky/95) & Eurasian (Newmarket/2/93) EIV A1 & A2 strains.
•Efficacy based on challenge studies for EIV.
•Novel adjuvant.
•Safe, all killed vaccine.
•Includes innovative pliable nasal applicator.

Benefits
•Flexible dose administration.
•Three dose regimen conforms to AAEP recommendations.
•No reversion to virulence concern.
•Minimal vaccine site reactions.

Advantages
Calvenza™ EIV/EHV is proven safe. Calvenza™ EIV/EHV is proven effective by challenge.

Dosage & Administration
Using aseptic technique inoculate horses IM with a 2 mL dose. Administer a second 2 mL dose IM in 3-4 weeks using a different injection site. Administer a third 2 mL dose in 3-4 weeks either IM or IN. Revaccinate annually and prior to anticipated exposure either IM or IN.

Precautions
Store at a temperature between 35° - 45° F (2° - 7° C). Protect from freezing. Shake well before using. Do not vaccinate within 21 days of slaughter.

Antidote: Epinephrine.

Uses
For the vaccination of healthy, susceptible horses 6 months of age or older, including pregnant mares, as an aid in the reduction of respiratory disease due to equine herpesvirus type 1 (EHV-1) and type 4 (EHV-4) and by equine influenza types A1 and A2.

Warning
This product has been tested under laboratory conditions and shown to meet all Federal standards for safety and efficacy in normal, healthy, immunocompetent animals. This level of performance may be affected by conditions such as stress, weather, nutrition, disease, parasitism, other treatments, individual idiosyncrasies or impaired immunological competency. These factors should be considered by the user when evaluating product performance or freedom from reactions.

Highlights
•Relevant types, quantities of EIV & EHV antigens with a novel adjuvant.
•First killed virus vaccine with relevant North American & Eurasian EIV A2 strains approved in the United States.
•Efficacy against EIV, EHV-1, EHV-4 demonstrated by challenge.
•Flexible routes of administration.
•Safe for use in pregnant mares